New promising discovery to fight idiopathic pulmonary fibrosis (IPF), a serious and often lethal lung disease.
In just 18 months, thanks to Artificial Intelligence (AI), a new therapeutic target was identified, an effective drug was developed and its safety verified.
So far, in fact, the experimental drugs tested have not been successful.
The work of "biogerontology" and its "InSilicoMeds" team was published in nature biotechnology and was made known on X by Nicola Marino, collaborator of "biogerontology".
The molecule in question, called INS018_055, is capable of inhibiting the Tnik gene and has shown excellent properties both in the laboratory and in animal studies, working orally, inhaled and topically and acting on different organs.
The molecule also has anti-inflammatory properties, proven effective in several studies.
Its safety and tolerability were then verified in two randomized controlled phase I clinical studies on healthy volunteers.
The role of AI was decisive, allowing researchers to identify Tnik as a new potential target to combat fibrosis, as well as helping the development of the molecule.
This work, the post reads, "underscores the enormous potential of AI to accelerate and improve drug discovery."
Reproduction reserved © Copyright ANSA